Denali Therapeutics (DNLI) Stock Forecast & Price Target

$18.74 -0.85 (-4.34%)

As of 04:00 PM Eastern

Denali Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
2

Buy
12

Based on 14 Wall Street analysts who have issued ratings for Denali Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for DNLI.

Consensus Price Target

$38.91
107.63% Upside

According to the 14 analysts' twelve-month price targets for Denali Therapeutics, the average price target is $38.91. The highest price target for DNLI is $87.00, while the lowest price target for DNLI is $24.00. The average price target represents a forecasted upside of 107.63% from the current price of $18.74.

Get the Latest News and Ratings for DNLI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors.

DNLI Analyst Ratings Over Time

Type	Current Forecast 1/15/24 to 1/14/25	1 Month Ago 12/16/23 to 12/15/24	3 Months Ago 10/17/23 to 10/16/24	1 Year Ago 1/15/23 to 1/15/24
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	11 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$38.91	$38.90	$38.22	$48.50
Forecasted Upside	107.63% Upside	69.35% Upside	38.19% Upside	161.60% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

DNLI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DNLI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Denali Therapeutics Stock vs. The Competition

Type	Denali Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.93	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	107.63% Upside	24,950.25% Upside	14.85% Upside
News Sentiment Rating	Neutral News See Recent DNLI News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/7/2025	Baird R W 0 of 5 stars	J. Beatty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/7/2025	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$28.00 ➝ $24.00	+12.20%
1/7/2025	Robert W. Baird 2 of 5 stars		Initiated Coverage	Outperform	$31.00	+56.41%
1/7/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$90.00 ➝ $87.00	+338.95%
1/3/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Schram Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
12/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$37.00	+61.08%
Get the Latest News and Ratings for DNLI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
11/1/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$40.00 ➝ $45.00	+64.65%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/7/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
9/4/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$25.00 ➝ $29.00	+15.45%
8/2/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$26.00 ➝ $32.00	+49.18%
8/2/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$30.00 ➝ $26.00	+18.94%
4/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$70.00 ➝ $32.00	+65.29%
2/29/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$73.00 ➝ $50.00	+142.01%
9/6/2023	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$38.00	+59.40%
4/12/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$61.00 ➝ $63.00	+164.26%
3/2/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$85.00 ➝ $70.00	+156.41%
2/28/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$80.00 ➝ $50.00	+84.16%
1/30/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Goodman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00	+63.83%
1/30/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$50.00	+58.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 12:48 AM ET.

DNLI Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Denali Therapeutics is $38.91, with a high forecast of $87.00 and a low forecast of $24.00.
: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DNLI shares.
: According to analysts, Denali Therapeutics's stock has a predicted upside of 107.63% based on their 12-month stock forecasts.
: Over the previous 90 days, Denali Therapeutics's stock had 2 upgrades by analysts.
: Denali Therapeutics has been rated by research analysts at Baird R W, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Robert W. Baird, Stifel Nicolaus, and William Blair in the past 90 days.
: Analysts like Denali Therapeutics more than other "medical" companies. The consensus rating score for Denali Therapeutics is 2.93 while the average consensus rating score for "medical" companies is 2.82. Learn more on how DNLI compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:DNLI) was last updated on 1/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Stock Forecast & Price Target